Omnilux™ was originally developed at the Paterson Institute for Cancer Research. Its optimized intensity and adjustable dose function have been used in the treatment of thousands of non-melanoma lesions. It is especially effective in cosmetically sensitive areas and for lesions in poor healing sites. Compared with conventional modalities, treatment outcomes are excellent, with significantly fewer adverse events.[1,2]
Specifically, the use of Omnilux along with ALA-PDT 1,2 has been shown to be optimally effective in treating:
- Non-hyperkeratotic actinic keratoses (AKs) on the face, chest, and scalp.
- Bowen’s disease
- Superficial Basal cell carcinomas (sBCCs) (less than 2 mm thick).